This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
OPKO Health's (OPK) BioReference Starts Fan Testing Program
by Zacks Equity Research
OPKO Health's (OPK) BioReference commences mandatory, large-scale COVID-19 testing programs for fans for AFC Division Wild Card playoff game.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) continues to gain from solid prospects in EHR and strategic deals. However, intense competition remains a woe.
Here's Why You Should Hold on to Intuitive Surgical (ISRG) Now
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from improving adoption of da Vinci Surgical System. But weak operational performance is a woe.
Nevro's (NVRO) FDA Submission to Treat Patients With PDN
by Zacks Equity Research
Nevro's (NVRO) submission of a pre-market approval supplement to the FDA to seek approval for its Senza System can help in the treatment of chronic pain associated with PDN.
Why You Must Add Merit Medical (MMSI) Stock to Your Portfolio
by Zacks Equity Research
Investor optimism is high on Merit Medical (MMSI) stock, courtesy of solid prospects.
HMS Holdings (HMSY) to be Acquired by Gainwell for $3.4B
by Zacks Equity Research
HMS Holdings (HMSY) entered into an agreement to be acquired by Gainwell in an all-cash transaction deal worth about $3.4 billion.
Here's Why You Should Retain Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) continues to benefit from solid CVI and CSI product portfolios.
Intersect ENT (XENT) Banks on SINUVA Sales Amid COVID-19 Woes
by Zacks Equity Research
Intersect ENT's (XENT) potential in chronic sinusitis market and progress in SINUVA and PROPEL product lines are encouraging.
Masimo's (MASI) Telehealth Solution Helps in COVID-19 Crisis
by Zacks Equity Research
Masimo (MASI) is lending support to Renown Health through Masimo SafetyNet in order to manage the COVID-19 surge.
Here's Why You Should Retain AmerisourceBergen (ABC) Now
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.
Abiomed's (ABMD) ECMO Technology Completes Successful Treatment
by Zacks Equity Research
Abiomed (ABMD) successfully treats first two patients in the world with the help of its Breethe OXY-1 System.
Here's Why You Should Retain Stryker Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in its robotic-arm assisted surgery platform - Mako and broad product portfolio. However, pricing pressure raises concern.
NextGen (NXGN) Solutions Support COVID-19 Vaccine Distribution
by Zacks Equity Research
NextGen (NXGN) lends a hand to the nationwide rollout of COVID-19 vaccines through its robust EHR platform and integrated solutions.
IDEXX (IDXX) Gains on CAG Sales, Global Growth Remains Robust
by Zacks Equity Research
IDEXX (IDXX) sees sturdy gains in CAG Diagnostics recurring revenues, supported by high organic gains in both U.S. and International markets.
Syneos Health (SYNH) Buys Illingworth Research, Expands CRO Base
by Zacks Equity Research
Syneos Health (SYNH) is currently working on bringing greater flexibility to each customer study, based on data, people, process and technology.
Globus Medical (GMED) Gains From Robot Sales Amid Pandemic Blues
by Zacks Equity Research
Globus Medical (GMED) saw a visible rebound in its revenue trend in the third quarter.
Abbott (ABT) Broadens Pediatric Client Base With New Labeling
by Zacks Equity Research
Abbott's (ABT) HeartMate 3 LVAD or heart pump is an implantable device that pumps blood through the body in people whose hearts are too weak to do so naturally.
Cerner (CERN) to Buy Kantar Health to Enhance Clinical Research
by Zacks Equity Research
Cerner (CERN) agrees to acquire Kantar Health to drive safety and efficiency of clinical research across life sciences, pharmaceuticals and health care.
Here's Why You Should Retain AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to gain traction from its wide range of services, and Healthcare MSP. Intense competition remains a woe.
NextGen's (NXGN) HDH to Facilitate Health Information Exchange
by Zacks Equity Research
NextGen's (NXGN) HDH has been chosen by HI-BRIDGE HIE for secure sharing of patient health data from multiple sources.
Here's Why You Should Retain Fresenius Medical (FMS) Stock
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction from its broad range of dialysis products and services. However, intense competition remains a woe.
Cerner's (CERN) Simplified Digital Tools to Aid Health Systems
by Zacks Equity Research
Cerner (CERN) offers centralized digital ordering and monitoring for clients in order to help health systems.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.
Cerner's (CERN) Deal to Make Clinical Trials More Accessible
by Zacks Equity Research
Cerner (CERN) inks deal with Elligo Health Research to make clinical trials more accessible, while minimizing costs.
Here's Why You Should Retain Change Healthcare (CHNG) Stock
by Zacks Equity Research
Change Healthcare (CHNG) continues to benefit from robust payment accuracy business and strategic deals. However, intense competition remains a woe.